LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

Search

Myriad Genetics Inc

Slēgts

SektorsVeselības aprūpe

4.01 -6.96

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.98

Max

4.3

Galvenie mērījumi

By Trading Economics

Ienākumi

-20M

-43M

Pārdošana

-2.7M

211M

EPS

0.03

Peļņas marža

-20.18

Darbinieki

2,700

EBITDA

19M

-2.2M

Rekomendācijas

By TipRanks

Rekomendācijas

Neitrāls

Prognoze 12 mēnešiem

+171.19% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 5. aug.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-429M

710M

Iepriekšējā atvēršanas cena

10.97

Iepriekšējā slēgšanas cena

4.01

Ziņu noskaņojums

By Acuity

63%

37%

336 / 382 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

Myriad Genetics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 8. maijs 23:59 UTC

Top Ziņas
Peļņas

Naver 1Q Net Slumps on Higher Costs

2025. g. 8. maijs 23:39 UTC

Peļņas

OCBC 1Q Net Down on Lower Interest Income

2025. g. 8. maijs 23:01 UTC

Peļņas

Macquarie Raises Dividend After 5.5% Rise in Annual Profit -- Update

2025. g. 8. maijs 22:52 UTC

Peļņas

REA Expects Annual Listings Growth Despite April Decline

2025. g. 8. maijs 22:46 UTC

Peļņas

Macquarie Raises Dividend After 5.5% Rise in Annual Profit

2025. g. 8. maijs 23:45 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 8. maijs 23:45 UTC

Tirgus saruna

Nikkei May Rise as Tariffs Fears Ease -- Market Talk

2025. g. 8. maijs 23:41 UTC

Tirgus saruna

Gold Rises on Possible Technical Recovery; Gains May be Capped by Risk-on Mood -- Market Talk

2025. g. 8. maijs 23:30 UTC

Peļņas

Itau Unibanco 1Q Rev BRL45.02B >ITUB

2025. g. 8. maijs 23:29 UTC

Peļņas

Itau Unibanco 1Q EPS BRL1.03 >ITUB

2025. g. 8. maijs 23:22 UTC

Peļņas

Naver 1Q Net Profit Largely Met FactSet-Compiled Consensus

2025. g. 8. maijs 23:22 UTC

Peļņas

Naver 1Q Net KRW423.70B Vs. Net KRW555.80B >035420.SE

2025. g. 8. maijs 23:21 UTC

Peļņas

Naver 1Q Oper Pft KRW505.30B Vs. Pft KRW439.30B >035420.SE

2025. g. 8. maijs 23:21 UTC

Peļņas

Naver 1Q Rev KRW2.787T Vs. KRW2.526T >035420.SE

2025. g. 8. maijs 23:17 UTC

Peļņas

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.35B Vs. S$2.44B >O39.SG

2025. g. 8. maijs 23:17 UTC

Peļņas

Oversea-Chinese Banking Corp. 1Q Total Income S$3.66B Vs. S$3.63B >O39.SG

2025. g. 8. maijs 23:17 UTC

Peļņas

Oversea-Chinese Banking Corp. 1Q Net S$1.88B Vs. Net S$1.98B >O39.SG

2025. g. 8. maijs 23:05 UTC

Tirgus saruna

ANZ Could Cut Dividend by 10% From 2H -- Market Talk

2025. g. 8. maijs 23:05 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 8. maijs 22:28 UTC

Peļņas

REA Expects FY 2025 Listings Growth of 1-2%

2025. g. 8. maijs 22:28 UTC

Peļņas

REA Says April Listings Decline Reflects Year Ago Strength, Timing of Easter and Election

2025. g. 8. maijs 22:27 UTC

Peļņas

REA Says April Sydney, Melbourne Listings Both Down 16% on Year

2025. g. 8. maijs 22:27 UTC

Peļņas

REA Says April Residential Listings Fell by 11% on Year

2025. g. 8. maijs 22:26 UTC

Peļņas

REA 3Q Operating Expenses A$176 Million, Up 12% on Year

2025. g. 8. maijs 22:26 UTC

Peļņas

REA 3Q Free Cash Flow A$132 Million, Up 19% on Year

2025. g. 8. maijs 22:26 UTC

Peļņas

REA 3Q Operating Ebitda A$199 Million, Up 12% on Year

2025. g. 8. maijs 22:26 UTC

Peļņas

REA Nine-Months Free Cash Flow A$389 Million, Up 21% on Year

2025. g. 8. maijs 22:25 UTC

Peļņas

REA Nine-Months Operating Expenses A$513 Million, Up 15% on Year

2025. g. 8. maijs 22:25 UTC

Peļņas

REA Nine-Months Operating Ebitda A$734 Million, Up 19% on Year

2025. g. 8. maijs 22:25 UTC

Peļņas

REA 3Q Revenue A$374 Million, Up 12% on Year

Salīdzinājums

Cenas izmaiņa

Myriad Genetics Inc Prognoze

Cenas mērķis

By TipRanks

171.19% augšup

Prognoze 12 mēnešiem

Vidējais 11.58 USD  171.19%

Augstākais 20 USD

Zemākais 6 USD

Pamatojoties uz 15 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Myriad Genetics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

15 ratings

5

Pirkt

7

Turēt

3

Pārdot

Tehniskais rādītājs

By Trading Central

N/A / 7.55Atbalsts un pretestība

Īstermiņā

Weak Bearish Evidence

Vidējā termiņā

Weak Bearish Evidence

Ilgtermiņā

Weak Bearish Evidence

Noskaņojums

By Acuity

336 / 382 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Lāču" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Myriad Genetics Inc

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, Onsite Women's Health, and Flatiron Health, Inc.; and collaboration to study the use of MRD testing in breast cancer. The company was incorporated in 1992 and is headquartered in Salt Lake City, Utah.